Double or Triple?

I remember reading on HC many many years ago that the longer a company takes to release the results of clinical trials the higher the possibility of failure which at the time l did not believe. However this became a reality for me from which l learnt a very hard lesson.

Some on here think that the longer we wait the better the results will be and they may very well be right but there's no guarantees despite the cherry picked case study examples they've been throwing at us for years now. It is a possibility that Dep Docetaxel as a monotherapy failed to impress and that's why they moved into combinations looking for a better outcome and we do not know due to the veil of silence we experience otherwise the trial would have finished years ago as forecast (JF said PH2 would take 2 years max in 2017).

I have become concerned over the last 12 months that management appear to think the world is standing still waiting for Dep to come along as humanities saviour (tongue in cheek) The reality is enormous advances are being made in the oncology field particularly in immunotherapies and we may find these Dep chemotherapies and chemotherapies in general having a much smaller market share into the future.

Just throwing this out there for those who think topping up on SPL is the way to go. For me l'm looking beyond and placing my cash elsewhere.